We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$37M
1-Year Est. Return
63.54%
This Fund
S&P 500
This Quarter
Est. Return
-22.77%
1 Year Est. Return
+63.54%
3 Year Est. Return
+38.32%
5 Year Est. Return
+47.02%
10 Year Est. Return
+2,089.98%
AUM
$1.72B
AUM Growth
-$1.36B
(-44%)
Cap. Flow
-$888M
Cap. Flow
% of AUM
-51.56%
Top 10 Holdings %
Top 10 Hldgs %
32.97%
Holding
299
New
73
Increased
48
Reduced
40
Closed
96
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Glaukos
GKOS
|
+$37.8M |
| 2 |
Guardant Health
GH
|
+$19.9M |
| 3 |
Pulmonx
LUNG
|
+$15.2M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$13.5M |
| 5 |
LYRA
LYRA THERAPEUTICS INC
LYRA
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$18M |
| 2 |
C4 Therapeutics
CCCC
|
+$15.2M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$13.5M |
| 4 |
ICU Medical
ICUI
|
+$12.8M |
| 5 |
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
|
+$11.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.95% |
| 2 | Industrials | 0.3% |
| 3 | Consumer Staples | 0.27% |
| 4 | Materials | 0.11% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
PUT
Bausch Health
BHC
$2.34B
| $2.51M | 0.15% |
+300,000
| New | +$4.19M |
|
127
CALL
Veru
VERU
$45.9M
| $2.26M | 0.13% |
+20,000
| New | +$2.32M |
|
|
SNCE
128
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $2.22M | 0.13% |
55,320
+5,000
| +10% | +$365K |
|
129
CALL
Iovance Biotherapeutics
IOVA
$2.92B
| $2.21M | 0.13% |
+200,000
| New | +$2.62M |
|
|
NYXH
130
Nyxoah
NYXH
$157M
| $2.19M | 0.13% |
221,949
| – | – |
|
131
Insulet
PODD
$10.1B
| $2.18M | 0.13% |
+10,000
| New | +$2.27M |
|
132
Cogent Biosciences
COGT
$6.53B
| $2.15M | 0.13% |
+238,787
| New | +$1.63M |
|
133
CALL
Avita Medical
RCEL
$252M
| $2.14M | 0.12% |
450,000
| – | – |
|
134
Natera
NTRA
$45B
| $2.13M | 0.12% |
+60,159
| New | +$2.23M |
|
135
Arcutis Biotherapeutics
ARQT
$3.26B
| $2.13M | 0.12% |
100,000
-89,363
| -47% | -$1.83M |
|
136
Alpha Teknova
TKNO
$397M
| $2.11M | 0.12% |
251,112
| – | – |
|
137
GH Research
GHRS
$1.95B
| $2.08M | 0.12% |
208,527
| – | – |
|
138
CALL
Anavex Life Sciences
AVXL
$302M
| $2M | 0.12% |
200,000
| – | – |
|
139
Edwards Lifesciences
EW
$53.4B
| $1.97M | 0.11% |
+20,700
| New | +$2.14M |
|
|
AMRS
140
DELISTED
Amyris Inc.
AMRS
| $1.94M | 0.11% |
1,050,399
-1,411,037
| -57% | -$4.15M |
|
|
AVDL
141
DELISTED
Avadel Pharmaceuticals
AVDL
| $1.93M | 0.11% |
+789,181
| New | +$3.24M |
|
|
CUTR
142
CALL
DELISTED
Cutera, Inc.
CUTR
| $1.88M | 0.11% |
50,000
-585,000
| -92% | -$30.9M |
|
|
SONX
143
DELISTED
Sonendo, Inc.
SONX
| $1.76M | 0.1% |
1,023,424
| – | – |
|
144
CALL
Apyx Medical
APYX
$127M
| $1.76M | 0.1% |
+300,000
| New | +$1.54M |
|
|
QTNT
145
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $1.6M | 0.09% |
166,550
-87,385
| -34% | -$1.86M |
|
146
PUT
TG Therapeutics
TGTX
$7.33B
| $1.58M | 0.09% |
+371,000
| New | +$2.32M |
|
147
Exelixis
EXEL
$12.6B
| $1.56M | 0.09% |
+75,000
| New | +$1.55M |
|
|
APEN
148
DELISTED
Apollo Endosurgery, Inc.
APEN
| $1.56M | 0.09% |
427,057
| – | – |
|
149
CALL
Atara Biotherapeutics
ATRA
$77.7M
| $1.56M | 0.09% |
+8,000
| New | +$1.31M |
|
150
Standard BioTools
LAB
$302M
| $1.36M | 0.08% |
850,000
| – | – |
|
Similar funds
CI
RH
ICP
GC
BAM
CM
AP
ACM
Pura Vida Investments's Q2 2022 Portfolio in Review
As of Q2 2022, Pura Vida Investments held 299 positions worth $1.72B, down 44% from $3.08B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Pura Vida Investments withdrew a net $888M in Q2 2022, closing 96 positions and reducing 40 holdings. Its most notable exit was C4 Therapeutics, an estimated $15.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 24% a quarter earlier, followed by Industrials and Consumer Staples.
Against the trend, Pura Vida Investments opened a new position in Glaukos worth $36.2M.
- Pura Vida Investments's largest Q2 2022 buy was Glaukos: 796,600 shares worth $36.2M.
- Pura Vida Investments added most to Guardant Health in Q2 2022, an estimated $19.9M increase.
- Pura Vida Investments's biggest Q2 2022 reduction was Vertex Pharmaceuticals, cutting an estimated $18M.
- Pura Vida Investments fully exited C4 Therapeutics in Q2 2022, selling an estimated $15.2M.
- Pura Vida Investments's ten largest holdings make up 33% of its $1.72B portfolio in Q2 2022.
- Pura Vida Investments opened 73 new positions and closed 96 in Q2 2022.
- Pura Vida Investments's portfolio value fell 44% quarter-over-quarter to $1.72B.
Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.